Vtv Therapeutics Inc. · NASDAQ:VTVT
Vtv Therapeutics — Investor Presentation (May 2025)
19 slides from Vtv Therapeutics's investor presentation, May 16, 2025
Slide 1: Improving the Lives of Millions of People Living with Type 1 Diabetes
1 Nasdaq: VTVT Improving the Lives of Millions of People Living with Type 1 Diabetes May 2025
Slide 2: Forward-Looking Statements
2 THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) THE DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCT
Slide 3: Experienced Leadership with Decades of Life Sciences Expertise
3 Experienced Leadership with Decades of Life Sciences Expertise Rich Nelson Chief Business Officer Carmen Valcarce, PhD Chief Scientific Officer Thomas Strack, MD Chief Medical Officer Dan Kirby SVP Strategic Ops Paul Sekhri Chair, President & CEO Martin Lafontaine Chief Commercial Officer
Slide 4: Living with T1D is Like Driving on a Narrow And Dangerous Road
4 TOO MUCH INSULIN TOO LITTLE INSULIN Living with T1D is Like Driving on a Narrow And Dangerous Road No FDA approved oral therapies to help maintain glucose control for the 1.6M living type 1 diabetes Hyperglycemia Hypoglycemia !
Slide 5: Cadisegliatin: A Large Opportunity in a Long-Underserved Market
5 Which may involve multiple daily insulin injections, wearing of an infusion device, frequent blood glucose monitoring, carb counting and dose titration, exercise and diet management, fear of hypoglycemia…1,6 ~ 9.4 M with T1D globally expected to grow to 17.4 M globally by 20401,2 Based on the ADA
Slide 6: Cadisegliatin: Potential to be First Oral Adjunct Therapy for T1D
6 Cadisegliatin: Potential to be First Oral Adjunct Therapy for T1D 1: Akturk HK, et al., T1D Exchange Quality Improvement Collaborative; Factors Associated With Improved A1C Among Adults With Type 1 Diabetes in the United States. Clin Diabetes; 2: Breakthrough T1D. Type 1 diabetes incidence and pre
Slide 7: Cadisegliatin: Liver-Selective Glucokinase Activator that Preserves GK-GKRP Interaction
7 GK = glucokinase; GKRP= glucokinase regulating protein Cadisegliatin: Liver-Selective Glucokinase Activator that Preserves GK-GKRP Interaction • Glucokinase acts as a glucose sensor and regulates glucose metabolism in the liver and pancreas • Cadisegliatin is designed to only interact with the glu
Slide 8: In People who do not Live with Type 1 Diabetes
8 When blood sugar is low Stored glycogen is broken down into glucose and released to maintain glucose homeostasis Glucokinase Insulin Glucose Glycogen Portal Vein In People who do not Live with Type 1 Diabetes: Glucokinase and insulin play essential roles in the liver to maintain glucose homeostasi
Slide 9: In People who Live with Type 1 Diabetes
9 When blood sugar is high Glucokinase activity is diminished due to low insulin, reducing glucose metabolism and glycogen storage Hypoglycemia Patient must take exogenous insulin Glucose Portal Vein Low insulin in the portal vein decreases glucokinase activity in the liver, hindering the metabolism
Slide 10: Cadisegliatin, a Glucokinase Activator, Restores Glucose Metabolism in the Liver
10 Portal Vein cadisegliatin Glucokinase activation by cadisegliatin in the liver lowers blood glucose, improves glucose homeostasis and glycogen storage Glucokinase Cadisegliatin, a Glucokinase Activator, Restores Glucose Metabolism in the Liver Hyperglycemia Hypoglycemia Hyperglycemia Hypoglycemia
Slide 11: Proof-of-Concept Clinical Data for Cadisegliatin in T1D and T2D
11 AGATA Phase 2 Study in T2D1 Reduction of HbA1c by 0.9% vs. metformin (p < 0.01) No difference to metformin with regards to hypoglycemia or hyperlipidemia over 6 months N = 190; US Study Proof-of-Concept Clinical Data for Cadisegliatin in T1D and T2D 1: Vella A, et al. Targeting hepatic glucokinas
Slide 12: Cadisegliatin Significantly Reduced Hypoglycemia and HbA1c v. Insulin Alone
12 Randomized, Double-Blind, Placebo (insulin alone) Controlled 2-Part Study of ~100 patients. A total of 49 patients in the treatment groups received 800mg daily of cadisegliatin. Cadisegliatin Significantly Reduced Hypoglycemia and HbA1c v. Insulin Alone1 SimpliciT1 Phase 2 Trial in patients with
Slide 13: No Observed Increased Risk of Ketoacidosis with Cadisegliatin vs. Insulin Alone
13 No Observed Increased Risk of Ketoacidosis with Cadisegliatin vs. Insulin Alone1 SimpliciT1 Phase 2 Trial in patients with T1D Abnormal Ketones > 0.4 mmol/L Abnormal Ketones > 0.6 mmol/L 1: Klein KR et al. The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive st
Slide 14: Cadisegliatin was Well-Tolerated Across People Living with T1D
14 Cadisegliatin was Well-Tolerated Across People Living with T1D1 1: Klein KR et al. The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b/2 adaptive study of TTP399, a hepatoselective glucokinase activator, for adjunctive treatment of type 1 diabetes. Diabetes Care. 2021 Ap
Slide 15: Cadisegliatin Did Not Adversely Impact Lipids in People Living with T1D
15 Cadisegliatin Did Not Adversely Impact Lipids in People Living with T1D1 Fasting Lipid Changes from Baseline in Type 1 Diabetes Patients1 Cadisegliatin 800 mg (n=40) Placebo (n=45) Fasting TG (mg/dL) Baseline 90 (87) 90 (49) Change from Baseline @EoS -4.5 (82) -2.5 (37) Fasting HDL (mg/dL) Baseli
Slide 16: Cadisegliatin Phase 3 CATT1 Study
16 Cadisegliatin Phase 3 CATT1 Study* – Informed by FDA Advice and Published Guidance for Endpoint Selection, Exposure and Population Criteria CATT1 Study Target Enrollment: • 150 subjects at • 20-25 US sites Primary endpoint: Incidence of Level 2 (based on study CGM) and Level 3 (based on blinded c
Slide 17: Broader Portfolio Continues to Offer Additional Upside and Shareholder Value
17 Product Indication Pre-clinical Phase 1 Phase 2 Phase 3 Partners + Rights PDE4 Inhibitor HPP737 Psoriasis Asia, excl. Japan RAGE Antagonist Azeliragon Glioblastoma Orphan Drug Designation Pancreatic Cancer Orphan Drug Designation Brain Metastasis (from Breast Cancer) Orphan Drug Designation Pneum
Slide 18: Cadisegliatin: Late-Stage Program with Potential to be the First Approved Oral Adjunct Therapy
18 Cadisegliatin: Late-Stage Program with Potential to be the First Approved Oral Adjunct Therapy for T1D in the U.S. Derisked by Phase 1 and 2 data (n>500) which showed positive impact on hypoglycemia and HbA1C Granted Breakthrough Therapy designation by FDA Completed $51M PIPE in February 2024 wit
Slide 19: Thank You!
19 Nasdaq: VTVT Thank You ! May 2025